Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Terbasil 250mg tablets, PA2315/099/001, Recall, One Batch
Notice type:
Recall
Date:
13/09/2024
We wish to advise you that one batch of Terbasil 250mg tablets, PA2315/099/001, is being recalled with immediate effect.
This recall is to
pharmacy level.
The reason for the recall is due to visible contamination on a small number of tablets within this batch.
Pharmacists can download a copy of the
pharmacy recall letter
.
Wholesalers can download a copy of the
wholesaler recall letter
.
Product name or type:
Terbasil 250mg tablets
Authorisation Number:
PA2315/099/001
Serial Or Batch Number And Expiry Date:
Batch number: D2203262
Expiry Date: 11/2025
Authorisation Holder:
Accord Healthcare Ireland Ltd
Recall Classification:
Pharmacy level recall
Target Audience:
Pharmacists
Wholesalers
Actions To Be Taken:
Information for pharmacists:
Pharmacists are requested to please take the following actions:
1. Immediately identify and quarantine any units of this batch which you have in your pharmacy. For hospital pharmacists, this includes stock on wards, in clinics and at any other relevant locations within your hospital.
2. Return quarantined units to your supplier, indicating that they are being returned as a result of this recall action.
3. If you have supplied units of this batch to any other pharmacy, clinic or other such establishment, please forward a copy of the pharmacy recall letter to them, and request they quarantine and return any unused units to you.
Replacement stock of this product is currently unavailable, and unimpacted stock is expected to be available by the first week of November 2024.
Information for patients:
If you have any queries, please contact your pharmacist.
Adverse reactions should be reported to Accord (medinfo@accord-healthcare.com) and to the HPRA (medsafety@hpra.ie).
« Back
Date Printed: 16/10/2024